MiNK Therapeutics (INKT) has been awarded a grant from the National Institute of Allergy and Infectious Diseases, a part of the National Institutes of Health. The grant will support development of MiNK’s allo-iNKT cell therapy platform for the prevention and treatment of graft-versus-host disease (GvHD) following hematopoietic stem cell transplantation, in collaboration with the University of Wisconsin.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INKT:
- MiNK Therapeutics Reports Q1 2025 Progress and Financials
- Mink Therapeutics’ Earnings Call Highlights Progress and Optimism
- Positive Outlook for MiNK Therapeutics: Promising Clinical Developments and Financial Performance
- MiNK Therapeutics: Promising Clinical Trials and Strategic Plans Justify Buy Rating
- MiNK Therapeutics reports Q1 EPS (70c) vs ($1.10) last year